METHYLENE BLUE AS RESCUE THERAPY FOR COVID-19 PATIENTS WHO FAILED TO RESPOND TO OTHER THERAPIES (FIRST REPORT)
Journal of Case Reports in Medical Science,
There is currently no consensus on specific pharmacological treatments for COVID-19 and there is debate about the efficacy and safety of antiviral drugs. The aim of this study is to show the effect of the reduced form of Methylene blue (MB) as the last option of treatment to rescue patients who did not respond to Remdesivir, Interferon-β, and Favipiravir therapies. Ten hospitalized severe COVID-19 patients (who failed to respond to Remdesivir, Interferon-β, and Favipiravir) were administered oral MB (1 mg/kg every 8 hours for two days, followed by 1mg/kg every 12 hours for the next days). These patients recovered completely. MB can be used in the treatment of COVID-19 patients. For the treatment of COVID-19 patients, in addition to fluid therapy and oxygen support, different types of drugs are required simultaneously, such as anti-viral agents, antibiotics, anticoagulants, immunomodulatory drugs, and antioxidants. MB possesses all of these properties along with anti-hypoxemia and anti-respiratory distress features and can therefore be included in the clinical management of COVID-19.
Clinical Trials.gov Identifier: NCT04370288; IRCT20191228045924N1
- methylene blue
How to Cite
Zhao M, Zhang J, Li H, et al. Recent progress of antiviral therapy for coronavirus disease 2019. European journal of pharmacology. 2020;24:173646.
Sulkowski MS, Cooper C, Hunyady B, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nature reviews Gastroenterology & hepatology. 2011; 8(4):212-23.
Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering; 2020.
Alamdari DH, Moghaddam AB, Amini S, et al. Application of methylene blue-vitamin C–N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. European Journal of Pharmacology. 2020; 885:173494.
Hamidi-Alamdari D, Hafizi-Lotfabadi S, Bagheri-Moghaddam A, et al. Methylene blue for treatment of hospitalized COVID-19 patients: A randomized, controlled, open-label clinical trial, phase 2. Revista de investigación clínica. 2021;73(3):190-8.
Janssen DJ, Ekström M, Currow DC, et al. COVID-19: guidance on palliative care from a European Respiratory Society international task force. Eur Respir J. 2020;56(3).
Smith T, Bushek J, LeClaire A, Prosser T. COVID-19 drug therapy. Elsevier; 2020.
McPherson RA. Henry's Clinical Diagnosis and Management by Laboratory Methods: First South Asia Edition_e-Book. Elsevier India; 2017.
Gendrot M, Andreani J, Duflot I, Boxberger M, Le Bideau M, Mosnier J, et al. Methylene blue inhibits replication of SARS-CoV-2 in vitro. International Journal of Antimicrobial Agents. 2020;56(6):106202.
Gendrot M, Jardot P, Delandre O, Boxberger M, Andreani J, Duflot I, Le Bideau M, et al. In Vitro Evaluation of the Antiviral Activity of Methylene Blue Alone or in Combination against SARS-CoV-2. Journal of Clinical Medicine. 2021;10(14):3007.
Bojadzic D, Alcazar O, Buchwald P. Methylene blue inhibits the SARS-CoV-2 spike–ACE2 protein-protein interaction–a mechanism that can contribute to its antiviral activity against COVID-19. Frontiers in pharmacology. 2020;11:600372.
Andreu GL. The rationale for methylene blue utility against SARS-CoV-2 infection complications. Journal of Pharmacy & Pharmacognosy Research. 2021;9(3):379-96.
Alfarouk KO, Alhoufie ST, Hifny A, Schwartz L, Alqahtani AS, Ahmed SB, Alqahtani AM, Alqahtani SS, Muddathir AK, Ali H, Bashir AH. Of mitochondrion and COVID-19. Journal of Enzyme Inhibition and Medicinal Chemistry. 2021;36(1):1258-67.
Abstract View: 229 times
PDF Download: 1 times